Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies

Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickl...

Full description

Saved in:
Bibliographic Details
Published in:Materials Science & Engineering C 2021-01, Vol.118, p.111427-111427, Article 111427
Main Authors: Hasanpour, Akram, Esmaeili, Fariba, Hosseini, Hossein, Amani, Amir
Format: Article
Language:English
Subjects:
Blood compatibility
Coaxial electrospray
Drug Carriers
In vivo studies
mPEG-PLGA nanoparticles
Nanoparticles
Particle Size
Polyesters
Polyethylene Glycols
Streptokinase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. [Display omitted] •Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.
ISSN:0928-4931
1873-0191
DOI:10.1016/j.msec.2020.111427